focus -WSS

focus

author：knowledge 2025-09-05 11:22:41 - browse：36

Mitch McConnell, after the 81-year-old GOP leader froze at the microphones as he arrived for a news conference, at the Capitol in Washington. -- health coverage from STAT — J. Scott Applewhite/AP

The handling of Senate Minority Leader Mitch McConnell’s abrupt medical issue this week is raising concerns among medical experts that the event sent a potentially dangerous public-health message — that when someone experiences an episode with symptoms like McConnell’s, they can simply return to work as though nothing had happened.

McConnell experienced the episode on Wednesday — freezing and remaining silent for about 20 seconds during a press conference, then showing signs of disorientation — and was led away by aides while cameras rolled.

Minutes later, the Kentucky senator, 81, returned to the press briefing and said, “I’m fine.” He didn’t answer specific questions about whether he was examined by a doctor. A McConnell aide later said the senator had felt light-headed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： 3 trends to watch in health tech's hiring outlook for 2024

WSS

ASCO: Palliative care found as helpful given virtually as in person

Kaiser's Risant Health gobbled up Geisinger. Who is next?

U.K. sequencing study surfaces new findings about tumor DNA

JPM: CVS says Medicare Advantage patients are impacting profits

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Antibiotic resistance and the global rise in human conflict

hotspot

focus

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Woman returns to dialysis after doctors remove transplanted pig kidney

In Memoriam: Notable people who died in 2023

JPM: CVS says Medicare Advantage patients are impacting profits

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The FDA must approve intranasal treatments for anaphylaxis

Anesthesiologist group: stop taking Ozempic before surgery

Ultragenyx gene therapy for rare liver ailment succeeds in late

BioMarin wins approval for gene therapy to treat hemophilia A

J&J to buy cancer drug developer Ambrx Biopharma

focus

A single drug, study failures leave Anavex with nothing but cash

Ahead of JPM, here's who's profiting most in health care

Burning questions for the 2024 JPM Healthcare Conference

FDA's Pazdur wants cancer trials to range beyond China alone

A single drug, study failures leave Anavex with nothing but cash

Antibiotic resistance and the global rise in human conflict

leisure time

explore

focus

leisure time